| http://www.w3.org/ns/prov#value | - Myriad Genetics, a molecular diagnostics specialist, has seen its stock falling (and heavily short-sold) due in part to concerns over Medicare's reimbursement rate for its genetic test that identifies which women are at greater risk of ovarian and breast cancer.
|
